The Journal of Maltese Science – "Perfect Outcast" Edition

[Hunor]

The Journal of Maltese Science - "Perfect Outcast" Edition
04.07.829

Effects of Crystal Cardamine

Prof. P. Ferrari et al

---

Introduction

---

The behavioral effects of administered new crystal cardamine (CryCard) were examined in 2500 Slave under controlled laboratory conditions on Planet Albegna, Sirocco Base and the physiological effects of oral administered new crystal cardamine were examined in 500 Slave under controlled laboratory conditions on Galicia Research Station.

The 50 mg / 70 kg and 100 mg / 70 kg doses of crystal cardamine significantly improved subjects’ performance on the in vivo tests above levels observed either prior to inhaled cardamine administration or when placebo was administered.

To our knowledge, this is the first experimental demonstration that administered crystal cardamine from genetically modified cardamine plant (GMCP) can improve behavioral performance in subjects. In addition, the duration of cognitive effects in this study was longer than previously reported with inhaled or intravenous cardamine.

The purpose of the present study was to assess the effects of oral administrated, prepared crystal cardamine on human performance using the tests on Galicia Research Station, which has revealed performance enhancing effects with crystal cardamine. We also assessed behavioral effects to try to replicate prior findings suggesting that crystal cardamine may safely transforms non-Outcast users into Outcast-eligible individuals on Planet Albegna, Sirocco Base.

---

Results

---

Behavioral measures:
Administration of the 50 and 100 mg doses of crystal cardamine significantly improved cognitive performance above placebo levels, although the two active doses were not significantly different from each other. The time-course and magnitude of crystal cardamine effects on cognitive performance were similar during the first and second dose-effect determinations, thereby providing a within subject replication of these effects. Peak effects generally occurred 30-100 minutes after administration of the 50 and 100 mg doses with each of the measures. In post-hoc comparisons, performance at 60 min after placebo administration was significantly degraded compared to pre-cardamine levels. In contrast, performance at 15 and 120 min after administration of the 50 mg dose and at 15, 30, 90, and 120 min after administration of the 100 mg dose was significantly improved cognitive functions compared to pre-cardamine levels.

Visual-analog ratings:
The 50 and 100 mg doses increased subject ratings of crystal cardamine effects and stimulated significantly above placebo levels. The effects of the two active doses did not differ significantly from each other, The 100 mg but not the 50 mg dose increased ratings of vigorous, tireless, and self-confidence significantly above placebo levels.

Physiological measures:
Heart rate:
Crystal cardamine increased heart rate as a graded function of dose Peak effects occurred 2-15 min after administration. Effects of the 50 and 100 mg doses were discernible by 10-20 min after crystal cardamine administration and generally remained significantly above placebo levels through the observation after crystal cardamine administration. There was a significant interaction between dose and dosing sequence with this measure, apparently due to a diminution of the effects of the 50 mg dose during the second dose-effect determination.

Systolic blood pressure:
The 50 and 100 mg doses of crystal cardamine increased systolic pressure as an orderly function of dose. Like the effects on heart rate. Effect on systolic pressure were similar across the two dose effect determinations, without malignant values, 5-10 units increased and kept constant.

Diastolic blood pressure:
The 50 mg and 100 mg doses not significantly increased diastolic pressure as an orderly function of dose, but diastolic pressure generally remained significantly above placebo levels.

Mean arterial pressure:
The 50 and 100 mg doses not increased mean arterial pressure significantly above placebo levels as an orderly function of crystal cardamine dose.

Skin temperature:
The 50 and 100 mg doses significantly decreased skin temperature below placebo levels; the two active doses did not differ from each other. Peak effects occurred approximately 6 hours after crystal cardamine administration, at which time temperatures had decreased from pre-cardamine levels by an average of 1.0, 8.2 and 7.1 degrees with the placebo, 50 and 100 mg doses, respectively. Crystal cardamine's effects on skin temperature were discernible by 15-30 min after administration, and the effects of both active doses remained significantly below placebo levels until 8 hours after crystal cardamine administration.

---

Discussion

---

In summary, then, this is the first report to document that crystal cardamine (CryCard) produced by genetically modified cardamine plant (GMCP) can enhance psychic and physiological performance in subjects who are not Outcasts origin. Those effects were associated with characteristic changes in cognitive functions and in daily activity, although the duration of the later effects was longer than expected. Future studies assessing the generality of crystal cardamine's performance effects across different tasks and dosing regimens and assessing the genetic changes in test subjects and bio-psycho-social changes in the macro environment.

---

---